Related Experiment Video
Updated: May 13, 2025
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.6K
Optimization of nanobody caplacizumab via computational design
Juping Huang1, Yu He1, Zhenjia Gan1
1Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University at Shanghai, 200062, China.
Physical Chemistry Chemical Physics : PCCP
|April 14, 2025
Summary
Caplacizumab treats thrombotic thrombocytopenic purpura (TTP) by blocking von Willebrand factor (VWF). This study optimized caplacizumab using computational methods, creating a variant with enhanced binding affinity for VWF A1.
Area of Science:
- Biochemistry
- Molecular Biology
- Computational Chemistry
Background:
- Thrombotic thrombocytopenic purpura (TTP) is a critical condition caused by abnormal von Willebrand factor (VWF) multimers leading to microvascular thrombosis.
- Caplacizumab, a nanobody therapeutic, inhibits VWF-platelet interactions by targeting the VWF A1 domain.
Purpose of the Study:
- To elucidate the molecular mechanism of caplacizumab's regulation on the VWF A1-platelet glycoprotein Ib (GPIb) interaction using molecular dynamics simulations.
- To identify key residues at the caplacizumab-VWF A1 interface and engineer enhanced binding affinity through mutagenesis.
Main Methods:
- Molecular dynamics (MD) simulations were used to analyze the dynamic interaction between VWF A1 and GPIb under caplacizumab's influence.
- Alanine scanning and single-point saturation mutagenesis were performed to identify critical residues and assess binding free energy changes.
- Combinatorial mutations were designed to create an optimized caplacizumab variant.
Main Results:
- MD simulations revealed the allosteric regulation mechanism of caplacizumab on VWF A1-GPIb interaction.
- Identification of hotspot and coldspot residues influencing binding affinity was achieved.
- An optimized four-point mutant caplacizumab variant demonstrated significantly enhanced binding free energy with VWF A1.
Conclusions:
- The study provides theoretical insights into the allosteric regulation of nanobody therapeutics.
- An optimized caplacizumab variant with improved binding affinity was successfully designed.
- Findings support the development of next-generation antithrombotic therapies with enhanced precision and efficacy.
